Day One Announces VRK1 License Agreement And Research Collaboration With Sprint Bioscience; Day One To Make $3M Upfront Payment To Sprint, Sprint Will Be Eligible For Up To $313M In Milestones
Portfolio Pulse from Benzinga Newsdesk
Day One Biopharmaceuticals has entered into a license agreement and research collaboration with Sprint Bioscience. Day One will make an upfront payment of $3M to Sprint, and Sprint could be eligible for up to $313M in milestones.
August 16, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Day One's new agreement with Sprint Bioscience could lead to significant financial obligations, but also potential advancements in their research.
The agreement could lead to significant financial obligations for Day One, with an upfront payment of $3M and potential milestone payments of up to $313M. However, the collaboration could also lead to advancements in their research, which could potentially increase the company's value in the long term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100